Primary Myelofibrosis: all 431 studies
Page 4 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentActive, not recruitingNCT04576156Phase 3
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisActive, not recruitingNCT04562870Phase 2
- Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisActive, not recruitingNCT04562389Phase 3
- Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisActive, not recruitingNCT04517851Phase 2
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
- Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisTerminatedNCT04480086Phase 1
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
- Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingNCT04454658Phase 1
- A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
- Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisActive, not recruitingNCT04384692Phase 2
- A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyWithdrawnNCT04354727Phase 1/2
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingNCT04328844Phase 1
- Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
- Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in FranceCompletedNCT04282421
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingNCT04279847Phase 1
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 2
- Actuate 1901: 9-ING-41 in MyelofibrosisCompletedNCT04218071Phase 2
- Jaktinib for the Treatment of Ruxolitinib Intolerance of MyelofibrosisCompletedNCT04217993Phase 2
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk MyelofibrosisActive, not recruitingNCT04217356
- PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisWithdrawnNCT04054245Phase 2
- Ruxolitinib in Myelofibrosis Patients in Lombardy, ItalyStatus unknownNCT03959371
- Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking RuxolitinibTerminatedNCT03935555Phase 1
- MPN-RC 118 AVID200 in MyelofibrosisCompletedNCT03895112Phase 1
- Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.CompletedNCT03886415Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.CompletedNCT03869476Not applicable
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
- Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)Active, not recruitingNCT03645824Phase 2
- Extended Access of Momelotinib in Adults With MyelofibrosisActive, not recruitingNCT03441113Phase 2
- Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT03426969Early Phase 1
- Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary MyelofibrosisStatus unknownNCT03402399Not applicable
- Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With MyelofibrosisTerminatedNCT03386214Phase 1
- Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisTerminatedNCT03373877Phase 1
- Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor AvailabilityActive, not recruitingNCT03333187Phase 2
- Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in MyelofibrosisCompletedNCT03208803
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisActive, not recruitingNCT03165734Phase 3
- 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative NeoplasmsTerminatedNCT03121599Not applicable
- 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential ThrombocythemiaStatus unknownNCT03116542Not applicable
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
- Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)CompletedNCT02953704
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With MyelofibrosisCompletedNCT02917096Phase 1
- Interferon-pegyle α2a Efficiency and Tolerance in MyelofibrosisCompletedNCT02910258
- Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02871323Phase 1
- PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1
- PTCy and Ruxolitinib GVHD Prophylaxis in MyelofibrosisCompletedNCT02806375Phase 1/2
- Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02805868Early Phase 1
- Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1
- Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPegCompletedNCT02742324Phase 1/2
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)CompletedNCT02593760Phase 1
- A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in MyelofibrosisWithdrawnNCT02584777Phase 2
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesActive, not recruitingNCT02530034Phase 1
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
- Ruxolitinib in Combination With AutotransplantWithdrawnNCT02469974Not applicable
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With MyelofibrosisCompletedNCT02370706Phase 1
- Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutationCompletedNCT02311569Phase 2
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Myeloproliferative Neoplasms and Bone StructureStatus unknownNCT01816022
- Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for MyelofibrosisCompletedNCT01814475Phase 2
- JAK2 Inhibitors RUXOLITINIB in Patients With MyelofibrosisCompletedNCT01795677Phase 2
- Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT01787487Phase 2
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary MyelofibrosisTerminatedNCT01730248Phase 1
- Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
- Connect® Myeloid Disease RegistryTerminatedNCT01688011
- Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MFCompletedNCT01644110Phase 1/2
- An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
- Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2
- Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsCompletedNCT01398462Phase 1
- A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid NeoplasmsCompletedNCT01387763Phase 3
- A Phase 2 Study With IPI-926 in Patients With MyelofibrosisCompletedNCT01371617Phase 2
- Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary MyelofibrosisStatus unknownNCT01331603
- LBH589 (Panobinostat) for the Treatment of MyelofibrosisStatus unknownNCT01298934Phase 1/2
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT01236638Phase 2
- Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)SuspendedNCT01211691Phase 1/2
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- A Study in Myeloproliferative DisordersCompletedNCT01134120Phase 1
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With MyelofibrosisTerminatedNCT01014546Phase 1
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT00935987Phase 1/2
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisCompletedNCT00745550Phase 1/2
- Bone Marrow Transplant Chart Review for RICCompletedNCT00723333
- Reversible Secondary Myelofibrosis or Clonal Myeloproliferative DisorderTerminatedNCT00722254
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET GenesCompletedNCT00715247